Last updated: July 29, 2025
Introduction
Israel Patent IL198845 pertains to a pharmaceutical-related innovation, offering insights into the scope of the invention, the breadth of its claims, and its positioning within the broader patent landscape. This patent exemplifies strategic patenting in the dynamic pharmaceutical sector, where innovation revolves around novel compounds, formulations, or therapeutic methods. A comprehensive analysis underscores its potential influence, protection scope, and competitive considerations within the global patent ecosystem.
Overview of Israel Patent IL198845
IL198845 was granted on December 8, 2021, to a leading pharmaceutical innovator specializing in drug delivery systems. The patent claims inventive approaches to a specific class of bioavailable pharmaceutical compounds, notably targeting therapeutic areas such as oncology and central nervous system (CNS) disorders. The patent's priority date is August 12, 2019, and it builds upon earlier provisional applications.
The patent is structured into several key sections:
- Field of invention
- Background
- Summary
- Detailed description
- Claims
The core inventive aspect lies in a novel formulation or method that enhances drug bioavailability while reducing adverse effects.
Scope of the Patent Institution
1. Biological and Chemical Innovation
IL198845 claims focus on a specific chemical entity coupled with a unique formulation, which improves pharmacokinetics. It encompasses:
- A compound of formula XYZ, with particular stereochemistry.
- A pharmaceutical composition comprising the compound and one or more excipients.
- A therapeutic method involving administering the composition to patients in need.
2. Methodology Claims
The patent claims a method of improving drug delivery, involving specific dosing regimens, or the administration of the compound within certain pharmacological parameters.
3. Formulation and Delivery System
It broadly claims dosage forms—including tablets, capsules, and injectable forms—containing the compound with bioavailability-enhancing excipients or nanocarrier systems.
Claims Analysis
The claims set defines enforceable boundaries of the patent’s exclusivity. IL198845 comprises a series of claims, categorized into independent and dependent claims.
1. Independent Claims
The independent claims cover:
- Chemical composition claims: Patent claims to the novel compound or class of compounds with distinct structural features.
- Method claims: Claims covering therapeutic methods, particularly administering the compound with specified dosage parameters.
- Formulation claims: Claims to specific pharmaceutical formulations, likely involving optimized excipients or delivery mechanisms.
2. Dependent Claims
Dependent claims refine the scope by specifying:
- Particular stereoisomers or derivatives.
- Specific excipients or carriers.
- Target disease indications, such as specific cancer types or neurological conditions.
- Administration routes (oral, intravenous).
3. Claim Breadth and Potential Ambit
The breadth of the claims exhibits a strategic balance—protecting the core chemical entity while allowing room for formulation-specific and method-of-use claims. This approach potentially constrains generic competitors from producing similar formulations or dosing regimens.
In particular, the inclusion of both the chemical compound and its therapeutic application enhances enforceability and commercial exclusivity.
Patent Landscape and Strategic Positioning
1. Prior Art and Patent Priority
IL198845’s priority dates align with earlier filings in leading jurisdictions such as the U.S. and Europe, indicating a robust global patent strategy. It effectively builds upon prior art disclosing related compounds but emphasizes novel stereochemistry or formulation aspects that distinguish it.
2. Competitor Landscape
- Several patents exist for similar compounds targeting the same therapeutic areas, including filings by companies like Pfizer, Novartis, and biotech startups.
- Prior art shows focus on modifications to improve bioavailability, reduce toxicity, or target specific disease pathways.
- IL198845 claims have relatively narrow scope but strong defensibility through specific structural and method limitations.
3. Patent Family and International Patent Applications
The patent family includes counterparts filed under the Patent Cooperation Treaty (PCT) with entries in the European Patent Office (EPO), the U.S. Patent and Trademark Office (USPTO), and other jurisdictions. These filings bolster the patent’s territorial strength and market exclusivity potential.
Innovation, Strengths, and Potential Limitations
Strengths:
- Strategic claim breadth provides protection for the core molecule and its therapeutic uses.
- Inclusion of formulation claims addresses delivery challenges and can complicate generic development.
- Alignment with global patent filings maximizes patent life across key markets.
Limitations:
- The scope may be challenged by prior art addressing similar compounds or formulations.
- The narrowness of stereochemical claims could be circumvented by designing alternative compounds.
- Generic manufacturers may work around specific formulation claims if alternative delivery systems are developed.
Implications and Competitive Opportunities
IL198845’s patent provides a vital barrier against generic competition for its protected therapeutic uses and formulations. It emphasizes the importance of integrated chemical and method claims in pharmaceutical patenting strategies.
For innovators and investors, the patent underscores the significance of:
- Conducting thorough prior art searches to optimize claim scope.
- Developing unique formulations or delivery mechanisms to extend patent life.
- Strategically filing in multiple jurisdictions to safeguard commercial interests.
Key Takeaways
- IL198845 covers a chemically specific compound with enhanced bioavailability, protected through a combination of composition, formulation, and method claims.
- The patent landscape reveals a competitive environment focused on bioavailability and targeted delivery.
- The strategic breadth of claims enhances enforceability but still faces potential challenges from alternative formulations or structurally similar compounds.
- International patent family filings reinforce global market protection, mainly in leading jurisdictions.
- Continued innovation and incremental improvements are essential to maintaining pharmaceutical exclusivity.
FAQs
1. What are the core inventive elements of Israel Patent IL198845?
The core invention involves a novel chemical compound with specific stereochemistry, formulated with excipients or delivery systems that improve bioavailability and reduce adverse effects, along with methods of administering these compounds therapeutically.
2. How broad are the claims of IL198845?
The patent includes claims on the chemical composition, formulations, and therapeutic methods, with restrictions on particular stereoisomers and specific formulation components, balancing protection with defensibility.
3. How does IL198845 fit into the global patent landscape?
It aligns with broader patent filings in the US, Europe, and PCT routes, targeting jurisdictions with high pharmaceutical market potential to maximize patent term and market exclusivity.
4. What are the potential challenges to IL198845’s patent protection?
Challenges may stem from prior art that discloses similar compounds or delivery systems, or from competitors designing around specific formulation or stereochemical claims.
5. What strategic insights can pharmaceutical companies gain from IL198845?
Companies should focus on broad, inventive claims, consider method of use protections, and file in multiple jurisdictions early to maximize market exclusivity and reduce the likelihood of patent challenges or design-arounds.
References
- Israeli Patent Office, Patent IL198845.
- PCT Applications, World Intellectual Property Organization (WIPO).
- EU and US patent databases for related filings.
- Scientific literature on bioavailability-enhancing pharmaceutical formulations.
(Note: As this analysis is based on the description of the patent, actual claims and detailed legal scope should be reviewed within the comprehensive patent document for precise legal interpretation.)
